19 July 2018

NICE, 10 Spring Gardens, London, SW1A 2BU

Final Agenda 

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

Please note that this agenda is final and is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Minutes from the last Committee meeting held on 23 March 2016 – Part 1 only (open session)                                                                                                                                                                                                                                                                                         
  6. Appraisal of Darvadstrocel for treating complex perianal fistula in Crohn’s disease [ID960]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Dr Jane Adam – Part 1 only (open session)
    • 6.3. Presentation by the lead team – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of Dabrafenib in combination with trametinib for adjuvant treatment of resected BRAF V600 positive malignant melanoma [ID1226] 

    The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for dabrafenib in combination with trametinib for adjuvant treatment of resected BRAF V600 positive malignant melanoma and as a consequence this discussion will take place in a Part 2 session (Part 2 sessions are closed to public observers).

    • 7.1. Declarations of interest – Part 2 only (closed session)
    • 7.2. Introduction by the Chair, Dr Jane Adam – Part 2 only (closed session)
    • 7.3. Presentation by the lead team  Part 2 only (closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of Pertuzumab for the adjuvant treatment of HER2-positive breast cancer [ID1192]
    • 9.1. Declarations of interest – Part 1 only (open session)
    • 9.2. Introduction by the Vice Chair, Professor Iain Squire – Part 1 only (open session)
    • 9.3. Presentation by the Vice Chair, Professor Iain Squire – Part 1 AND part 2 (open and closed session)
    • 9.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Thursday 16 August 2018 at 10:00, NICE, 10 Spring Gardens, London, SW1A 2BU

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Thursday 5 July 2018Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Ana Uribe Echeverry.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 21 June 2018 to 05 July 2018
Registration is closed.